The statements in this document that are not historical facts are forward-looking statements that involve risks and uncertainties, and include the risk of achieving approval and successful launch of Natrecor(R), the timeliness and success of Scios and its partners in developing products, including a p38-kinase inhibitor, and the risk to Scios of reliance on a third party manufacturer such as for Eskalith
CR 450 mg.
Although the mood-stabilizing drug lithium (SmithKline Beecham's Eskalith
, generics) is broadly available and widely used as first-line therapy for BPD, its shortcomings have left room for improvement.
The decrease in revenues during the first quarter of 2000 is mainly attributed to a temporary shortage of Eskalith
CR, one of 5 products Scios sells for SmithKline Beecham.
Nasdaq: SCIO) today announced a possible temporary product shortage of Eskalith
CR (lithium carbonate) Controlled Release Tablets(R) 450 mg, one of five psychiatric products developed and manufactured by SmithKline Beecham that are now sold by Scios.
Schein, URL) Eskalith
(R) and Eskalith
CR(R) (SKF); Lithonate(R)